Compare STRA & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRA | AMLX |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 1996 | 2021 |
| Metric | STRA | AMLX |
|---|---|---|
| Price | $76.41 | $17.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $87.00 | $21.56 |
| AVG Volume (30 Days) | 261.1K | ★ 1.6M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | 15.85 | ★ 65.46 |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $997,137,000.00 | $380,786,000.00 |
| Revenue This Year | $4.71 | N/A |
| Revenue Next Year | $4.67 | N/A |
| P/E Ratio | $52.03 | ★ N/A |
| Revenue Growth | 57.23 | ★ 1612.94 |
| 52 Week Low | $69.70 | $7.48 |
| 52 Week High | $87.38 | $19.15 |
| Indicator | STRA | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 42.87 | 57.09 |
| Support Level | $72.13 | $12.14 |
| Resistance Level | $84.55 | $18.88 |
| Average True Range (ATR) | 2.67 | 1.01 |
| MACD | -0.59 | -0.13 |
| Stochastic Oscillator | 21.84 | 52.28 |
Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.